Serengen and LDC announce collaboration May 2022
Serengen’s DELs will fuel the drug discovery projects at the Lead Discovery Center in Dortmund.
16th August 2022
Serengen synthesises and screens DNA-Encoded Libraries (DEL) tailored to your project.
Our proprietary technology offers the fastest and most cost-efficient approach to hit identification that allows for serendipity and delivers high quality hits.
Accelerate early drug discovery
Perform today’s fastest and most economical hit identification and significantly speed up early drug discovery:
PHARMA
Access a unique DEL technology that allows to add a truly novel chemical space to your DEL screening decks.
BIOTECH
Benefit from serendipity in hit ID with a breakthrough DEL technology that offers lower hit attrition and lower follow-up costs.
START-UPS & RESEARCH ORGANISATIONS
Save time and budget by screening DELs that are designed for your target proteins.
What´s new
Serengen’s DELs will fuel the drug discovery projects at the Lead Discovery Center in Dortmund.
Satz et al. elaborate current status of DNA-encoded chemical library (DECL) technology.
Talk to our CEO Thorsten about how DELs can solve your hit identification and lead generation challenges!
+49 (0)231 999 50 902
+49 (0)231 999 50 902
*Required
I agree that the information I supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679.
